Retrospektive Untersuchung der Anti-VEGF-Behandlungsrealität und Wirksamkeit bei Patienten mit neovaskulärer altersabhängiger Makuladegeneration (nAMD) in Deutschland

Augood CA, Vingerling JR, De Jong PT et al (2006) Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 124:529–535

Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57–65

Chakravarthy U, Harding SP, Rogers CA et al (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382:1258–1267

Cohen SY, Mimoun G, Oubraham H et al (2013) Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 33:474–481

Finger RP, Wiedemann P, Blumhagen F et al (2013) Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study – a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 91:540–546

Friedman DS, O’colmain BJ, Munoz B et al (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122:564–572

Holz FG, Schmitz-Valckenberg S, Fleckenstein M (2014) Recent developments in the treatment of age-related macular degeneration. J Clin Invest 124:1430–1438

Holz FG, Tadayoni R, Beatty S et al (2014) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. doi:2010.1136/bjophthalmol-2014-305327 (Published Online First: Sep. 5, 2014)

http://www.bdoc.info/pdf/AMD_Stellungnahme_2009.pdf. Zugegriffen: 28. Juli 2104

http://www.bdoc.info/pdf/AMD_Stellungnahme_2010.pdf. Zugegriffen: 28. Juli 2104

http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf. Zugegriffen: 28. Juli 2104

https://www.institut-des-bewertungsausschusses.de/ba/babeschluesse/2014-06-25_ba328_2.pdf. Zugegriffen: 28. Juli 2014

Keenan TD, Kelly SP, Sallam A et al (2013) Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK. Br J Ophthalmol 97:1168–1172

Lucentis Lucentis Zusammenfassung; Stand: 22.01.2007

Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398

Muether PS, Hoerster R, Hermann MM et al (2013) Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251:453–458

Prokofyeva E, Zrenner E (2012) Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res 47:171–188

Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431